Risk of Pharmaceutical Business Dependence on Eloxatin
First written in FY2018. 11 of 23 entries say "Restated". Latest entry: FY2024.
Yakult Honsha moved to the "Worse" side of this theme in 2020, the same year as the typical company in this theme.
The whole theme swung hardest in 2017: 4 of 7 companies on the "Worse" side.
5 other companies' latest entry also says "Materialised".
- FY2024MaterialisedAnnual report
「As a result, overall pharmaceutical performance was below the previous fiscal year.」
Against a backdrop of dependence on Eloxatin, switching to generic drugs and cuts in official drug prices, pressure on pharmaceutical business earnings has continued to materialize as lower full-year performance. - FY2024-Q3MaterialisedAnnual report
「However, sales were affected by the increasing tendency of medical institutions to switch from the core product Eloxatin to generic drugs, as well as by reductions in official drug prices for most of the Company's products in the drug price revision implemented in April last year.」
Amid continued pressure on pharmaceutical business earnings from dependence on Eloxatin, switching to generic drugs and cuts in official drug prices, the impact on sales through the cumulative third quarter has continued to materialize. - FY2024-Q2MaterialisedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs in line with government policy, the Company conducted activities using its strength as the developer of the originator drug, namely its ability to provide information, with regard to its core product, the anticancer drug Eloxatin. However, sales were affected because official drug prices for most of the Company's products were reduced in the drug price revision implemented in April.」
Amid the continued increase in switching to generic drugs and cuts in official drug prices, the impact on sales in the pharmaceutical business, including Eloxatin, has materialized. - FY2024-Q1MaterialisedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs in line with government policy, the Company conducted activities using its strength as the developer of the originator drug, namely its ability to provide information, with regard to its core product, the anticancer drug Eloxatin. However, sales were affected because official drug prices for most of the Company's products were reduced in the drug price revision implemented in April.」
Amid the continued increase in switching to generic drugs and cuts in official drug prices, the impact on sales in the pharmaceutical business, including Eloxatin, has materialized. - FY2023MaterialisedAnnual report
「As a result, consolidated net sales in the pharmaceuticals manufacturing and marketing segment were ¥12,763 million, down 24.9% year on year.」
Against a backdrop of dependence on Eloxatin, switching to generic drugs and cuts in official drug prices, the decline in full-year sales in the pharmaceutical manufacturing and marketing business has materialized in performance. - FY2023-Q3MaterialisedAnnual report
「However, sales were affected by the reduction in the prices of most of the company's products in the drug price revision implemented in April last year, as well as by the termination in September of the promotional agreement with Servier Japan concerning the antineoplastic agent Onivyde®.」
In the pharmaceutical business, including core drugs such as Eloxatin, cuts in official drug prices and the termination of a promotion agreement have materialized as lower sales. - FY2023-Q2MaterialisedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs in line with government policy, the Company conducted activities using its strength as the developer of the originator drug, namely its ability to provide information, with regard to its core product, the anticancer drug Eloxatin. However, sales were affected because official drug prices for most of the Company's products were reduced in the drug price revision implemented in April.」
Amid the continued increase in switching to generic drugs and cuts in official drug prices, the pharmaceutical manufacturing and marketing segment's sales declined 16.1% year on year, with pressure on pharmaceutical business earnings reflected in performance. - FY2022-Q3RestatedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs in line with government policy, the Company conducted activities using its strength as the developer of the originator drug, namely its ability to provide information, so that its core product, the anticancer drug Eloxatin, would remain a treatment option for healthcare professionals.」
Amid the increasing tendency to switch to generic drugs, the Company continues activities to encourage selection of Eloxatin by using its ability to provide information. - FY2022-Q2RestatedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs in line with government policy, the Company conducted activities using its strength as the developer of the originator drug, namely its ability to provide information, so that its core product, the anticancer drug Eloxatin, would remain a treatment option for healthcare professionals.」
Amid the increasing tendency to switch to generic drugs, the Company continues activities to encourage selection of Eloxatin by using its ability to provide information. - FY2022-Q1RestatedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs in line with government policy, the Company conducted activities using its strength as the developer of the originator drug, namely its ability to provide information, so that its core product, the anticancer drug Eloxatin, would remain a treatment option for healthcare professionals.」
Amid the increasing tendency to switch to generic drugs, the Company continues activities to encourage selection of Eloxatin by using its ability to provide information. - FY2021MaterialisedAnnual report
「As a result, consolidated sales in the pharmaceutical manufacturing and marketing segment were ¥18,123 million, down 7.9% year on year.」
Against a backdrop of dependence on Eloxatin, switching to generic drugs, cuts in official drug prices and restrained medical consultations due to infectious diseases, full-year sales in the pharmaceutical manufacturing and marketing business declined 7.9% year on year. - FY2021-Q3RestatedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs, the Company conducted activities to encourage continued selection of its core product, the anticancer drug Eloxatin, by drawing on its strengths as the developer of the originator drug, including its ability to provide information and its relationships of trust with healthcare professionals.」
Amid the increasing tendency to switch to generic drugs, the Company continues activities to encourage selection of Eloxatin by using its ability to provide information and its relationships of trust with healthcare professionals. - FY2021-Q2RestatedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs, the Company conducted activities to encourage continued selection of its core product, the anticancer drug Eloxatin, by drawing on its strengths as the developer of the originator drug, including its ability to provide information and its relationships of trust with healthcare professionals.」
Amid the increasing tendency to switch to generic drugs, the Company continues activities to encourage selection of Eloxatin by using its ability to provide information and its relationships of trust with healthcare professionals. - FY2021-Q1RestatedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs, the Company conducted activities to encourage continued selection of Eloxatin by drawing on its strengths as the developer of the originator drug, including its ability to provide information and its relationships of trust with healthcare professionals.」
Amid the increasing tendency to switch to generic drugs, the Company continues activities to encourage selection of Eloxatin by using its ability to provide information and its relationships of trust with healthcare professionals. - FY2020MaterialisedAnnual report
「As a result, consolidated sales in the pharmaceutical manufacturing and marketing segment were ¥19,670 million, down 9.3% year on year.」
Against a backdrop of dependence on Eloxatin, switching to generic drugs and cuts in official drug prices, full-year sales in the pharmaceutical manufacturing and marketing business declined 9.3% year on year. - FY2020-Q3WorsenedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs, the Company conducted activities to encourage continued selection of Eloxatin by drawing on its strengths as the developer of the originator drug, including its ability to provide information and its relationships of trust with healthcare professionals.」
Amid the increasing tendency to switch to generic drugs, the Company continued activities to encourage selection of Eloxatin, but sales in the pharmaceutical manufacturing and marketing segment declined 8.0% year on year. - FY2020-Q2RestatedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs, the Company conducted activities to encourage continued selection of Eloxatin by drawing on its strengths as the developer of the originator drug, including its ability to provide information and its relationships of trust with healthcare professionals.」
Amid the increasing tendency to switch to generic drugs, the Company continues activities to maintain Eloxatin's share by using lectures, its ability to provide information and its relationships of trust with healthcare professionals. - FY2020-Q1RestatedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs, the Company conducted activities to encourage continued selection of Eloxatin by drawing on its strengths as the developer of the originator drug, including its ability to provide information and its relationships of trust with healthcare professionals.」
Amid the increasing tendency to switch to generic drugs, the Company continues activities to encourage the selection of Eloxatin by using its ability to provide information and its relationships of trust with healthcare professionals. - FY2019WorsenedAnnual report
「As a result, consolidated sales in the pharmaceutical manufacturing and marketing segment were ¥21,696 million, down 15.5% year on year.」
Against a backdrop of dependence on Eloxatin and switching to generic drugs, full-year sales in the pharmaceutical manufacturing and marketing business declined 15.5% year on year. - FY2019-Q3RestatedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs, the Company conducted activities to encourage continued selection of Eloxatin by drawing on its strengths as the developer of the originator drug, including its ability to provide information and its relationships of trust with healthcare professionals.」
Amid the increasing tendency to switch to generic drugs, the Company continues activities to encourage the selection of Eloxatin by using its ability to provide information and its relationships of trust with healthcare professionals. - FY2019-Q2RestatedAnnual report
「Although an increasing number of medical institutions are switching to generic drugs, the Company conducted activities to encourage continued selection of Eloxatin by drawing on its strengths as the developer of the originator drug, including its ability to provide information and its relationships of trust with healthcare professionals.」
Amid the increasing tendency to switch to generic drugs, the Company continues activities to encourage the selection of Eloxatin by using its ability to provide information and its relationships of trust with healthcare professionals. - FY2019-Q1RestatedAnnual report
「Although the number of medical institutions switching to generic drugs has been trending upward since generic versions of ELOXATIN were launched, we continued efforts to have them choose ELOXATIN by drawing on our strengths as the developer of the originator drug, including our ability to provide information and the trust we have built with healthcare professionals.」
Despite the increasing tendency of medical institutions to switch to generic drugs, the Company continues activities to maintain and expand Eloxatin's share by using its strengths as the developer of the originator drug, including its ability to provide information and its relationships of trust with healthcare professionals. - FY2018First statedAnnual report
「The Company's pharmaceutical business is heavily dependent on sales of the anticancer drug Eloxatin, but sales of Eloxatin have declined since the launch of generic drugs. As a result, sales in the Group's pharmaceutical business have declined in recent years, and this trend may continue in the future.」
The Company identifies dependence of its pharmaceutical business on a specific product and the decline in Eloxatin sales following the launch of generic drugs as separate risks.